• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1997-2007 年间台湾一家医学中心三种表型未分化鲍曼不动杆菌复合群中对亚胺培南、美罗培南、舒巴坦和多黏菌素耐药趋势的差异。

Difference in imipenem, meropenem, sulbactam, and colistin nonsusceptibility trends among three phenotypically undifferentiated Acinetobacter baumannii complex in a medical center in Taiwan, 1997-2007.

机构信息

Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

出版信息

J Microbiol Immunol Infect. 2011 Oct;44(5):358-63. doi: 10.1016/j.jmii.2011.01.032. Epub 2011 Jan 20.

DOI:10.1016/j.jmii.2011.01.032
PMID:21524973
Abstract

BACKGROUND

To determine whether the susceptibilities and the trends of nonsusceptibility of imipenem, meropenem, sulbactam, and colistin differed among Acinetobacter baumannii, Acinetobacter genomic species 3 (AGS 3), and Acinetobacter genomic species 13TU (AGS 13TU) over 11 years.

METHODS

A total of 1,039 nonduplicate blood isolates of A baumannii complex from bacteremic patients between 1997 and 2007 were collected at Taipei Veterans General Hospital and were identified to the species level using a multiplex polymerase chain reaction method and sequence analysis of 16S-23S intergenic spacer. The minimal inhibitory concentrations of antibiotics were determined by the agar dilution method.

RESULTS

The nonsusceptibility rates of carbepenems and sulbactam were highest in A baumannii, which also showed a trend toward increasing rate of carbapenems nonsusceptibility over the 11-year period of the study. AGS 13TU had the highest nonsusceptible rate to colistin, comparably increasing trend of carbapenem nonsusceptiblity as that of A baumannii, and is the only species with increasing sulbactam nonsusceptibility. AGS 3 had the lowest rate of nonsusceptibility to all four antimicrobial agents.

CONCLUSION

Although A baumannii had the highest nonsusceptibility rate to imipenem, meropenem, and sulbactam over the years, the higher rate of colistin nonsusceptibility and the emergence of nonsusceptibility of carbapenems and sulbactam in AGS 13TU suggested that this species might cause a great problem in the near future.

摘要

背景

为了确定在 11 年间,鲍曼不动杆菌、基因组种 3(AGS 3)和基因组种 13TU(AGS 13TU)对亚胺培南、美罗培南、舒巴坦和黏菌素的敏感性和非敏感性趋势是否存在差异。

方法

1997 年至 2007 年间,从台北荣民总医院血培养阳性的患者中收集了 1039 株非重复的鲍曼不动杆菌复合体分离株,使用多重聚合酶链反应方法和 16S-23S 基因间隔区序列分析对其进行种水平鉴定。采用琼脂稀释法测定抗生素的最小抑菌浓度。

结果

碳青霉烯类和舒巴坦的不敏感率在鲍曼不动杆菌中最高,且在研究的 11 年期间,碳青霉烯类不敏感率呈上升趋势。AGS 13TU 对黏菌素的不敏感率最高,与鲍曼不动杆菌相似,碳青霉烯类不敏感率呈上升趋势,也是唯一对舒巴坦不敏感率呈上升趋势的种。AGS 3 对所有四种抗菌药物的不敏感率最低。

结论

尽管鲍曼不动杆菌对亚胺培南、美罗培南和舒巴坦的不敏感率多年来一直最高,但由于 AGS 13TU 对黏菌素的不敏感率较高,以及碳青霉烯类和舒巴坦不敏感率的出现,该种可能在不久的将来成为一个大问题。

相似文献

1
Difference in imipenem, meropenem, sulbactam, and colistin nonsusceptibility trends among three phenotypically undifferentiated Acinetobacter baumannii complex in a medical center in Taiwan, 1997-2007.1997-2007 年间台湾一家医学中心三种表型未分化鲍曼不动杆菌复合群中对亚胺培南、美罗培南、舒巴坦和多黏菌素耐药趋势的差异。
J Microbiol Immunol Infect. 2011 Oct;44(5):358-63. doi: 10.1016/j.jmii.2011.01.032. Epub 2011 Jan 20.
2
Susceptibility of the Acinetobacter calcoaceticus-A. baumannii complex to imipenem, meropenem, sulbactam and colistin.醋酸钙不动杆菌-鲍曼不动杆菌复合体对亚胺培南、美罗培南、舒巴坦和黏菌素的敏感性。
Int J Antimicrob Agents. 2004 May;23(5):487-93. doi: 10.1016/j.ijantimicag.2003.09.026.
3
In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.碳青霉烯/舒巴坦合剂、多黏菌素、多黏菌素/利福平合剂及替加环素对耐碳青霉烯鲍曼不动杆菌的体外活性
J Antimicrob Chemother. 2007 Aug;60(2):317-22. doi: 10.1093/jac/dkm136. Epub 2007 May 31.
4
Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU.比较耐碳青霉烯类不动杆菌属种(鲍曼不动杆菌与 3 型和 13TU 型基因种)对抗菌药物组合的体外抗微生物药敏活性和协同作用。
Diagn Microbiol Infect Dis. 2011 Jul;70(3):380-6. doi: 10.1016/j.diagmicrobio.2011.03.003. Epub 2011 May 10.
5
In vitro activities of colistin and ampicillin/sulbactam against Acinetobacter baumannii.黏菌素和氨苄西林/舒巴坦对鲍曼不动杆菌的体外活性。
J Med Assoc Thai. 2011 Aug;94 Suppl 3:S95-100.
6
Synergistic activity of sulbactam combined with colistin against colistin-resistant Acinetobacter baumannii.舒巴坦与黏菌素联合对耐黏菌素鲍曼不动杆菌的协同活性。
Int J Antimicrob Agents. 2012 Feb;39(2):180-1. doi: 10.1016/j.ijantimicag.2011.10.001. Epub 2011 Nov 17.
7
Amino acid substitutions of quinolone resistance determining regions in GyrA and ParC associated with quinolone resistance in Acinetobacter baumannii and Acinetobacter genomic species 13TU.喹诺酮耐药决定区 GyrA 和 ParC 中的氨基酸取代与鲍曼不动杆菌和不动杆菌基因组种 13TU 的喹诺酮耐药相关。
J Microbiol Immunol Infect. 2012 Apr;45(2):108-12. doi: 10.1016/j.jmii.2011.09.001. Epub 2011 Dec 6.
8
Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases.黏菌素、利福平、亚胺培南和舒巴坦/氨苄西林单独或联合使用对产OXA-58碳青霉烯酶的流行多重耐药鲍曼不动杆菌分离株的比较活性。
Int J Antimicrob Agents. 2007 Dec;30(6):537-40. doi: 10.1016/j.ijantimicag.2007.07.007. Epub 2007 Sep 11.
9
Mechanisms of resistance to ciprofloxacin, ampicillin/sulbactam and imipenem in Acinetobacter baumannii clinical isolates in Taiwan.台湾地区鲍曼不动杆菌临床分离株对环丙沙星、氨苄西林/舒巴坦和亚胺培南耐药机制的研究。
Int J Antimicrob Agents. 2010 Apr;35(4):382-6. doi: 10.1016/j.ijantimicag.2009.12.009. Epub 2010 Feb 6.
10
Differences in phenotypic and genotypic characteristics among imipenem-non-susceptible Acinetobacter isolates belonging to different genomic species in Taiwan.台湾地区不同基因组种属的对亚胺培南耐药不动杆菌分离株表型和基因型特征的差异。
Int J Antimicrob Agents. 2009 Dec;34(6):580-4. doi: 10.1016/j.ijantimicag.2009.06.027. Epub 2009 Sep 3.

引用本文的文献

1
Multicenter Study of Clinical Features of Breakthrough Acinetobacter Bacteremia during Carbapenem Therapy.多中心研究碳青霉烯类治疗期间突破型鲍曼不动杆菌菌血症的临床特征。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00931-17. Print 2017 Sep.
2
Carbapenem Breakpoints for Acinetobacter baumannii Group: Supporting Clinical Outcome Data from Patients with Bacteremia.鲍曼不动杆菌属的碳青霉烯类药物敏感性断点:来自菌血症患者的支持性临床结果数据
PLoS One. 2016 Sep 19;11(9):e0163271. doi: 10.1371/journal.pone.0163271. eCollection 2016.
3
Comparative Phosphoproteomics Reveals the Role of AmpC β-lactamase Phosphorylation in the Clinical Imipenem-resistant Strain Acinetobacter baumannii SK17.
比较磷酸化蛋白质组学揭示AmpC β-内酰胺酶磷酸化在临床耐亚胺培南鲍曼不动杆菌SK17中的作用。
Mol Cell Proteomics. 2016 Jan;15(1):12-25. doi: 10.1074/mcp.M115.051052. Epub 2015 Oct 23.
4
The Acinetobacter baumannii group: a systemic review.鲍曼不动杆菌群:系统评价。
World J Emerg Med. 2013;4(3):169-74. doi: 10.5847/wjem.j.issn.1920-8642.2013.03.002.
5
Comparison between bacteremia caused by carbapenem resistant Acinetobacter baumannii and Acinetobacter nosocomialis.耐碳青霉烯鲍曼不动杆菌与医院不动杆菌引起菌血症的比较。
BMC Infect Dis. 2013 Jul 10;13:311. doi: 10.1186/1471-2334-13-311.
6
Clinical characteristics and outcomes of bacteremia due to different genomic species of Acinetobacter baumannii complex in patients with solid tumors.不同基因型鲍曼不动杆菌复合体致实体瘤患者菌血症的临床特征和转归。
Infection. 2012 Feb;40(1):19-26. doi: 10.1007/s15010-011-0187-4. Epub 2011 Sep 2.